CYP3A5 Polymorphism in Circulating Tumor Cells Confers an Increased Disease-Free Survival in DLBCL Patients Treated with R-CHOP

    March 2025 in “ OncoTargets and Therapy ”
    Rafael Cerón Maldonado, Adolfo Martínez Tovar, Christian Omar Ramos Peñafiel … Irma Olarte‐Carrillo
    Studysummary This study found that in circulating tumor cells from non-invasive liquid biopsies, the GG genotype of the CYP3A5 A6986G affects longer disease-free survival in DLBCL patients, highlighting the significance of circulating biomarkers for prognostic evaluation.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on dovepress.com →
    Discuss this study in the Community →

    Research cited in this study 1

    1. Pilot Study: Genetic Distribution of AR, FGF5, SULT1A1, and CYP3A5 Polymorphisms in Male Mexican Population with Androgenetic Alopecia PubMed · 2022